Osteoarthritis, Arthritis, Surgery, Infection, Inflammation, Disability, Hemorrhage
Conditions
Keywords
blood loss, bipolar sealer, aquamantys, total knee replacement, primary total knee arthroplasty
Brief summary
This study will compare the clinical outcomes for patients undergoing a total knee replacement using a bipolar sealer, the Aquamantys® System, as compared to standard electrocautery. Total blood loss during the hospital stay and knee mobility and discharge factors will be analyzed.
Interventions
DEVICEElectrocautery
Use of electrocautery in tourniquet and tourniquetless total knee replacement surgery
DEVICEBipolar sealer Aquamantys
Aquamantys use in tourniquet and tourniquetless total knee replacement.
Sponsors
Medtronic Surgical Technologies
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient is ≥18 years of age * Patient has failed conservative therapy of osteoarthritis of the knee and has been listed to undergo primary TKA * Patient is willing and able to provide written informed consent. * Pre-assessment Haemoglobin ≥ 11.0g/dl * Patient is suitable to receive spinal anaesthesia with no peripheral nerve blocks * Patients willing to undergo blood transfusion
Exclusion criteria
* Patients that are listed for unicondylar or revision TKA * Patients who are being converted from a previous high tibial osteotomy and a previous unicondylar knee arthroplasty * Fixed motor deficit thus affecting functional assessment of the knee * Patients presenting with a non-osteoarthritis degenerative knee diagnosis * Patients presenting with known contralateral knee osteoarthritis requiring simultaneous bilateral TKA * Patients presenting with a history of previous knee infection * Patients presenting with a pre-operative knee range of motion \< 85° * Knee deformity greater than 20 degrees varus or valgus * Patients presenting with a history of bleeding disorders and/or are on chronic blood anticoagulation therapy * Patients with significantly impaired renal function (defined by EGFR \>30) * Patients with allergy or sensitivity to non-steroidal anti-inflammatory drugs, ropivacaine, ketoprofen or adrenaline * Patients presenting with an internal cardiac defibrillator * Women who are pregnant * Evidence of active (systemic or local) infection at time of surgery * Patients who have habitual opioid use * Patients who have a psychiatric or mental illness which could impair the consent process or ability to complete patient-report questionnaires * Morbid obesity \[BMI \> 40\] * Patients who are unwilling to undergo blood transfusion, if necessary * Patients who are receiving any implant used in conjunction with a customised-cutting block system * Any patient who cannot or will not provide written informed consent for participation in the study * Those whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood Loss | upto to 72 hrs after surgery | The primary outcome will be total blood loss throughout the hospital stay. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rehabilitation | 6-weeks | Discharge criteria evaluated. |
Countries
United Kingdom
Outcome results
None listed